Literature DB >> 17963743

Interactions of attention-deficit/hyperactivity disorder therapeutic agents with the efflux transporter P-glycoprotein.

Hao-Jie Zhu1, Jun-Sheng Wang, Jennifer L Donovan, Yan Jiang, Bryan B Gibson, C Lindsay DeVane, John S Markowitz.   

Abstract

The objective of this study was to assess the potential interactions of the drug transporter P-glycoprotein with attention-deficit/hyperactivity disorder (ADHD) therapeutic agents atomoxetine--and the individual isomers of methylphenidate, amphetamine, and modafinil utilizing established in vitro assay. An initial ATPase assay indicated that both d- and l-methylphenidate have weak affinity for P-glycoprotein. The intracellular accumulation of P-glycoprotein substrates doxorubicin and rhodamine123 in the P-glycoprotein overexpressing cell line LLC-PK1/MDR1 was determined to evaluate potential inhibitory effects on P-glycoprotein. The results demonstrated that all compounds, except both modafinil isomers, significantly increased doxorubicin and rhodamine123 accumulation in LLC-PK1/MDR1 cells at higher concentrations. To investigate the P-glycoprotein substrate properties, the intracellular concentrations of the tested compounds in LLC-PK1/MDR1 and P-glycoprotein negative LLC-PK1 cells were measured in the presence and absence of the P-glycoprotein inhibitor PSC833. The results indicate that the accumulation of d-methylphenidate in LLC-PK1 cells was 32.0% higher than in LLC-PK1/MDR1 cells. Additionally, coadministration of PSC833 leads to 52.9% and 45.6% increases in d-modafinil and l-modafinil accumulation, respectively, in LLC-PK1/MDR1 cells. Further studies demonstrated that l-modafinil transport across LLC-PK1/MDR1 cell monolayers in the basolateral-to-apical (B-A) direction was significantly higher than in the apical-to-basolateral (A-B) direction. PSC833 treatment significantly decreased the transport of l-modafinil in B-A direction. In conclusion, our results suggest that all tested agents with the exception of modafinil isomers are relatively weak P-glycoprotein inhibitors. Furthermore, P-glycoprotein may play a minor role in the transport of d-methylphenidate, d-modafinil, and l-modafinil.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17963743      PMCID: PMC2659508          DOI: 10.1016/j.ejphar.2007.09.035

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  44 in total

Review 1.  Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults.

Authors:  Laurence L Greenhill; Steven Pliszka; Mina K Dulcan; William Bernet; Valerie Arnold; Joseph Beitchman; R Scott Benson; Oscar Bukstein; Joan Kinlan; Jon McClellan; David Rue; Jon A Shaw; Saundra Stock
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2002-02       Impact factor: 8.829

2.  Is attention deficit hyperactivity disorder increasing among girls in the US? Trends in diagnosis and the prescribing of stimulants.

Authors:  Linda M Robison; Tracy L Skaer; David A Sclar; Richard S Galin
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

3.  Risperidone and paliperidone inhibit p-glycoprotein activity in vitro.

Authors:  Hao-Jie Zhu; Jun-Sheng Wang; John S Markowitz; Jennifer L Donovan; Bryan B Gibson; C Lindsay DeVane
Journal:  Neuropsychopharmacology       Date:  2006-08-23       Impact factor: 7.853

Review 4.  Attention-deficit/hyperactivity disorder and comorbidity.

Authors:  T Spencer; J Biederman; T Wilens
Journal:  Pediatr Clin North Am       Date:  1999-10       Impact factor: 3.278

5.  In vitro P-glycoprotein affinity for atypical and conventional antipsychotics.

Authors:  David W Boulton; C Lindsay DeVane; Heidi L Liston; John S Markowitz
Journal:  Life Sci       Date:  2002-05-31       Impact factor: 5.037

6.  Double-blind, placebo-controlled study of single-dose amphetamine formulations in ADHD.

Authors:  R S James; W S Sharp; T M Bastain; P P Lee; J M Walter; M Czarnolewski; F X Castellanos
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2001-11       Impact factor: 8.829

Review 7.  The Texas Children's Medication Algorithm Project: Report of the Texas Consensus Conference Panel on Medication Treatment of Childhood Attention-Deficit/Hyperactivity Disorder. Part I. Attention-Deficit/Hyperactivity Disorder.

Authors:  S R Pliszka; L L Greenhill; M L Crismon; A Sedillo; C Carlson; C K Conners; J T McCracken; J M Swanson; C W Hughes; M E Llana; M Lopez; M G Toprac
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2000-07       Impact factor: 8.829

8.  Specificity of doxorubicin versus rhodamine-123 in assessing P-glycoprotein functionality in the LLC-PK1, LLC-PK1:MDR1 and Caco-2 cell lines.

Authors:  I C van der Sandt; M C Blom-Roosemalen; A G de Boer; D D Breimer
Journal:  Eur J Pharm Sci       Date:  2000-09       Impact factor: 4.384

Review 9.  Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-deficit hyperactivity disorder.

Authors:  J S Markowitz; K S Patrick
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

10.  Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo.

Authors:  S Hoffmeyer; O Burk; O von Richter; H P Arnold; J Brockmöller; A Johne; I Cascorbi; T Gerloff; I Roots; M Eichelbaum; U Brinkmann
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-28       Impact factor: 11.205

View more
  7 in total

1.  Using stimulants for attention-deficit/hyperactivity disorder: clinical approaches and challenges.

Authors:  Jonathan R Stevens; Timothy E Wilens; Theodore A Stern
Journal:  Prim Care Companion CNS Disord       Date:  2013-03-28

Review 2.  Clinically Significant Drug-Drug Interactions with Agents for Attention-Deficit/Hyperactivity Disorder.

Authors:  Georgios Schoretsanitis; Jose de Leon; Chin B Eap; John M Kane; Michael Paulzen
Journal:  CNS Drugs       Date:  2019-12       Impact factor: 5.749

Review 3.  Atomoxetine: A Review of Its Pharmacokinetics and Pharmacogenomics Relative to Drug Disposition.

Authors:  Guo Yu; Guo-Fu Li; John S Markowitz
Journal:  J Child Adolesc Psychopharmacol       Date:  2016-02-09       Impact factor: 2.576

4.  PharmGKB summary: methylphenidate pathway, pharmacokinetics/pharmacodynamics.

Authors:  Tyler Stevens; Katrin Sangkuhl; Jacob T Brown; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2019-08       Impact factor: 2.089

5.  Acute Hyperkinetic Movement Disorders as a Multifactorial Pharmacodynamic Drug Interaction Between Methylphenidate and Risperidone in Children and Adolescents.

Authors:  Mohamed Mohamoud; Qi Chen; David Croteau; Carmen Cheng; Keith Burkhart; Donna A Volpe; Cindy Kortepeter; Dorothy Demczar; Marc Stone
Journal:  J Clin Psychopharmacol       Date:  2022 May-Jun 01       Impact factor: 3.118

Review 6.  In vitro study methodologies to investigate genetic aspects and effects of drugs used in attention-deficit hyperactivity disorder.

Authors:  Edna Grünblatt; Jasmin Bartl; Zoya Marinova; Susanne Walitza
Journal:  J Neural Transm (Vienna)       Date:  2012-07-26       Impact factor: 3.575

7.  An in vitro evaluation of guanfacine as a substrate for P-glycoprotein.

Authors:  Nancy K Gillis; Hao-Jie Zhu; John S Markowitz
Journal:  Neuropsychiatr Dis Treat       Date:  2011-08-26       Impact factor: 2.570

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.